UPDATE 1-COVID vaccine developer Codiak files for US bankruptcy protection

Reuters

2023/03/27

(Adds background)

March 27 (Reuters) - Codiak BioSciences Inc said on Monday it has filed for Chapter 11 bankruptcy protection and will seek to sell its assets, months after the COVID-19 vaccine developer announced job cuts.

The company reduced its workforce by 37% to 53 full-time employees in August last year to extend its cash runway. As of Sept. 30, 2022 the company had cash and cash equivalents of $51.8 million.

Codiak previously said it would prioritize its coronavirus vaccine development program that was funded by the Coalition for Epidemic Preparedness Innovations.

The company said on Monday its executive management team will leave the firm effective April 7.

(Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2322440091"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2322440091\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2322440091?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-03-27 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2322440091","market":"us","top_or_hot":-1,"title":"UPDATE 1-COVID vaccine developer Codiak files for US bankruptcy protection","media":"Reuters","content":"<html><body><p>(Adds background)</p><p>      March 27 (Reuters) - Codiak BioSciences Inc    said on Monday it has filed for Chapter 11 bankruptcy protection and will seek to sell its assets, months after the COVID-19 vaccine developer announced job cuts.</p><p>   The company reduced its workforce by 37% to 53 full-time employees in August last year to extend its cash runway. As of Sept. 30, 2022 the company had cash and cash equivalents of $51.8 million.</p><p>   Codiak previously said it would prioritize its coronavirus vaccine development program that was funded by the Coalition for Epidemic Preparedness Innovations.</p><p>   The company said on Monday its executive management team will leave the firm effective April 7.</p><p> (Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta)</p><p>((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-COVID vaccine developer Codiak files for US bankruptcy protection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-COVID vaccine developer Codiak files for US bankruptcy protection\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2023-03-27 19:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>(Adds background)</p><p>      March 27 (Reuters) - Codiak BioSciences Inc    said on Monday it has filed for Chapter 11 bankruptcy protection and will seek to sell its assets, months after the COVID-19 vaccine developer announced job cuts.</p><p>   The company reduced its workforce by 37% to 53 full-time employees in August last year to extend its cash runway. As of Sept. 30, 2022 the company had cash and cash equivalents of $51.8 million.</p><p>   Codiak previously said it would prioritize its coronavirus vaccine development program that was funded by the Coalition for Epidemic Preparedness Innovations.</p><p>   The company said on Monday its executive management team will leave the firm effective April 7.</p><p> (Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta)</p><p>((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴資本持倉","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2322440091","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2322440091","pubTimestamp":1679916873,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"(Adds background)      March 27 (Reuters) - Codiak BioSciences Inc    said on Monday it has filed fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"更新1-COVID疫苗开发商Codiak申请美国破产保护","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDAK":0.9},"content_text":"(Adds background)      March 27 (Reuters) - Codiak BioSciences Inc    said on Monday it has filed for Chapter 11 bankruptcy protection and will seek to sell its assets, months after the COVID-19 vaccine developer announced job cuts.   The company reduced its workforce by 37% to 53 full-time employees in August last year to extend its cash runway. As of Sept. 30, 2022 the company had cash and cash equivalents of $51.8 million.   Codiak previously said it would prioritize its coronavirus vaccine development program that was funded by the Coalition for Epidemic Preparedness Innovations.   The company said on Monday its executive management team will leave the firm effective April 7. (Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta)((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}